Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Evercore ISI

Vaxcyte (NASDAQ:PCVX - Get Free Report) was upgraded by equities research analysts at Evercore ISI to a "strong-buy" rating in a report released on Monday, March 31st,Zacks.com reports.

A number of other equities analysts also recently weighed in on PCVX. Needham & Company LLC lowered their target price on shares of Vaxcyte from $140.00 to $90.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. The Goldman Sachs Group reduced their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Guggenheim reissued a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Trading Down 6.2 %

Shares of NASDAQ PCVX traded down $2.01 during midday trading on Monday, reaching $30.50. The company's stock had a trading volume of 1,678,931 shares, compared to its average volume of 1,681,066. The stock has a 50 day simple moving average of $73.42 and a 200-day simple moving average of $88.87. The stock has a market capitalization of $3.93 billion, a price-to-earnings ratio of -6.62 and a beta of 1.26. Vaxcyte has a fifty-two week low of $29.57 and a fifty-two week high of $121.06.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. As a group, equities analysts anticipate that Vaxcyte will post -4.21 EPS for the current year.

Insiders Place Their Bets

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,250 shares of company stock valued at $3,170,738. 3.10% of the stock is currently owned by insiders.

Institutional Trading of Vaxcyte

Several institutional investors have recently modified their holdings of PCVX. Vanguard Group Inc. lifted its holdings in Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock worth $979,184,000 after buying an additional 521,204 shares during the period. RA Capital Management L.P. lifted its stake in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock worth $992,914,000 after acquiring an additional 485,436 shares during the period. Capital Research Global Investors boosted its holdings in Vaxcyte by 26.8% in the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after acquiring an additional 1,312,302 shares during the last quarter. State Street Corp increased its position in Vaxcyte by 1.1% during the 3rd quarter. State Street Corp now owns 3,405,743 shares of the company's stock valued at $389,174,000 after purchasing an additional 38,596 shares during the period. Finally, Franklin Resources Inc. raised its holdings in Vaxcyte by 3.0% during the 4th quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock worth $234,884,000 after purchasing an additional 82,997 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.